학술논문
P-292 Ongoing phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma (MM)
Document Type
Abstract
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 2:S198-S198
Subject
Language
ISSN
2152-2650